Diagnostic and therapeutic approaches to multiple myeloma patients: ‘Real-world’ data from representative multicentre 
treatment surveys in Germany between 2008 and 2011

Moehler,Thomas M.; Merz,Maximilian; Kellermann,Lenka; Goldschmidt,Hartmut; Knauf,Wolfgang

doi:10.3892/ol.2016.5375

Diagnostic and therapeutic approaches to multiple myeloma patients: ‘Real-world’ data from representative multicentre treatment surveys in Germany between 2008 and 2011

Authors:
- Thomas M. Moehler
- Maximilian Merz
- Lenka Kellermann
- Hartmut Goldschmidt
- Wolfgang Knauf
View Affiliations

Affiliations: Department of Medicine V, University of Heidelberg, Heidelberg 69120, Germany, Oncology Information Service, Freiburg 79098, Germany, Onkologische Gemeinschaftspraxis, Frankfurt 60389, Germany
Published online on: November 10, 2016 https://doi.org/10.3892/ol.2016.5375
Pages: 5043-5051
Copyright: © Moehler et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A survey was conducted to investigate the standard of care for multiple myeloma in Germany, in order to clarify the status of implementation of international and national treatment guidelines. In addition, the changes in disease management over time were investigated by comparison with surveys conducted in 2008 and 2009. The survey captured a representative sample of 478 myeloma patients with a mean age of 67.9 years across various stages of the disease. Diagnostic approaches, prognostic aspects and treatment decisions were evaluated based on a survey conducted in 2011 in 58 representative centres in Germany, including university and non‑university hospitals and office‑based haematologists. Data were collected from chart reviews and were analysed retrospectively. Over time, an increasing number of patients were investigated for cytogenetic abnormalities (53%). Age <69 years and lack of comorbid conditions were major determinants for cytogenetic testing. Bortezomib/chemotherapy‑based regimens have become the preferred first‑line treatments independent of planning autologous blood stem cell transplantation (ASCT) in first‑line therapy. Thalidomide‑ and lenalidomide‑based combination therapies are typically used as second‑line treatments in 31% of patients. Compared with previous reviews, the frequency of ASCT was stable, at ~30% of patients. Younger age and indicators of more severe disease, such as the presence of CRAB criteria, influenced the decision in favour of performing ASCT. Compared to previous surveys, the requirement for erythropoietin and granulocyte colony‑stimulating factor, as well as transfusions of red blood cells and platelets, respectively, have decreased considerably. In summary, novel agents have led to a substantial change in the first‑line and relapsed treatment approaches. Age and comorbidities remain major factors influencing treatment decisions, but cytogenetic testing to investigate myeloma‑related risk profiles is increasingly integrated. The use of novel agents has affected supportive care, with reduced necessity for substitute blood products and reduced administration of bone marrow-stimulating factors.

View Figures

View References

1	Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, et al: Hillengass Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 25:189–195. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, et al: European perspective on multiple myeloma treatment strategies: Update following recent congresses. Oncologist. 17:592–606. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Sanz R Garcia, Powles R, Lentzsch S, Chen W Ming, Hou J, Jurczyszyn A, et al: Durie International myeloma working group recommendations for global myeloma care. Leukemia. 28:981–992. 2014. View Article : Google Scholar : PubMed/NCBI
4	Pulte D, Gondos A and Brenner H: Improvement in survival of older adults with multiple myeloma: Results of an updated period analysis of SEER data. Oncologist. 16:1600–1603. 2011. View Article : Google Scholar : PubMed/NCBI
5	Brenner H, Gondos A and Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 111:2521–2526. 2008. View Article : Google Scholar : PubMed/NCBI
6	Klein B, Seckinger A, Moehler T and Hose D: Molecular pathogenesis of multiple myeloma: Chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res. 183:39–86. 2011. View Article : Google Scholar : PubMed/NCBI
7	Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, et al: European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 99:232–242. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gaultney JG, Redekop WK, Sonneveld P and Uyl-de Groot CA: Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value. Expert Rev Anticancer Ther. 12:839–854. 2012. View Article : Google Scholar : PubMed/NCBI
9	Knauf W, Kellermann L, Poenisch W, Einsele H, Straka C, Frohn C and Goldschmidt H: How to treat multiple myeloma - a representative multicentre treatment survey. Onkologie. 33:604–610. 2010. View Article : Google Scholar : PubMed/NCBI
10	Durie BG and Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
11	Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child A, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
12	Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, et al: Combination of international scoring system 3, high lactate dehydrogenase and t (4;14) and/or del (17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 32:2173–2180. 2014. View Article : Google Scholar : PubMed/NCBI
13	Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 92:3131–3136. 1998.PubMed/NCBI
14	van Rhee F, Giralt S and Barlogie B: The future of autologous stem cell transplantation in myeloma. Blood. 124:328–333. 2014. View Article : Google Scholar : PubMed/NCBI
15	Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 23:9227–9233. 2005. View Article : Google Scholar : PubMed/NCBI
16	Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, et al: Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 371:895–905. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, et al: Current multiple myeloma treatment strategies with novel agents: A European perspective. Oncologist. 15:6–25. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, et al: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 30:2946–2955. 2012. View Article : Google Scholar : PubMed/NCBI
19	Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 366:1759–1769. 2012. View Article : Google Scholar : PubMed/NCBI
20	McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 366:1770–1781. 2012. View Article : Google Scholar : PubMed/NCBI
21	Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, et al: Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data. Lancet Oncol. 15:333–342. 2014. View Article : Google Scholar : PubMed/NCBI
22	Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, Lehners N, Egerer G, Ho AD, Goldschmidt H and Neben K: Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients. Cancer. 119:2438–2446. 2013. View Article : Google Scholar : PubMed/NCBI